{
    "symbol": "AZN",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-09 15:03:04",
    "content": " The floor 2, the confidence for that is based on the -- again, we've got a Phase II data set that's already been published, the Opel data set which showed really high response rate of around 90% and a high durable progression-free survival which if recapitulated in the floor to would represent a significant improvement over the standard of care and something that's in line with what the much smaller data set that we've seen from the an avant combination has seen."
}